Feac logo
by
Forbion

Initial Public Offering on Nasdaq

USD 127 million
Joint Bookrunner
;

Forbion European Acquisition Corp.

Joint Bookrunner

Kempen & Co acted as Joint Bookrunner in the upsized USD 127 million Nasdaq IPO of Forbion European Acquisition Corp.

Transaction highlights

  • Forbion European Acquisition Corp. (“FEAC”), a special purpose acquisition company (“SPAC”), raised USD 127 million through an IPO on the Nasdaq Global Market (“Nasdaq”) with proceeds intended to be used to pursue a business combination in the life sciences industry in Europe
  • A total of 11.0 million units have been sold in the offering for USD 10.00 per unit, raising proceeds of USD 110 million (or a total of USD 126.5 million including the underwriters’ over-allotment option). The deal was upsized from the originally envisaged USD 100 million
  • Each unit consists of one Class A ordinary share and one-third of one redeemable warrant to each investor. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of USD 11.50 per share subject to adjustment, terms and limitations as described in the prospectus
  • The sponsor of the SPAC is an affiliate of Forbion, one of Europe’s largest and most experienced healthcare investment firms
  • This transaction marks Kempen & Co’s third SPAC transaction in 2021 after the USD 128 million Nasdaq IPO of European Biotech Acquisition Corp. in March 2021 and the €250 million Euronext Amsterdam IPO of ESG Core Investments in February 2021

Company description

  • FEAC was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While FEAC may pursue an initial business combination opportunity in any business, industry, sector or geographical location, it intends to capitalize on the ability of our management team to identify promising late-stage opportunities in the life sciences industry in Europe
  • FEAC will primarily seek to identify, but are not limited to, a company within the European life sciences industry, with a high potential product candidate or candidates in later stages of clinical development that would benefit from the capital and management support, thereby unlocking value
  • The members of the FEAC’s management team are associated with Forbion, one of the leading brands within the European life sciences industry, supported by a successful track record and strong reputation with co-investors, entrepreneurs, and large pharmaceutical companies

Background Kempen & Co Life Sciences & Healthcare

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

  • Co-Lead Manager in the USD 115 million Nasdaq Initial Public Offering by IO Biotech
  • Lead manager in the USD 110 million Global Offering of Merus
  • Joint Global Coordinator and Joint Bookrunner in MaaT Pharma’s €31.5 million Euronext IPO
  • Co-Manager in the USD 460 million Capital Increase by Ascendis Pharma 
  • Joint Bookrunner in the SEK 324 million Capital Increase by Calliditas Therapeutics
  • Joint Global Coordinator & Joint Bookrunner in the SEK 380 million Capital Increase by Xbrane Biopharma
  • Joint Global Coordinator in the €34.1m Capital Increase by Transgene
  • Joint Global Coordinator & Joint Bookrunner in the SEK 141 million Capital Increase by Immunicum
  • Lead Manager in the USD 63.8 million Nasdaq Initial Public Offering by Molecular Partners
  • Joint Bookrunner in the SEK 301 million Capital Increase by Q-linea
  • Co-Manager in the USD 176 million Nasdaq Initial Public Offering by Achilles Therapeutics 
  • Joint Bookrunner in the €30.0 million Capital Increase by GenSight Biologics
  • Lead Manager in the USD 101 million Nasdaq Initial Public Offering by LAVA Therapeutics
  • Joint Bookrunner in the USD 120 million Nasdaq Initial Public Offering by European Biotech Acquisition Corp (EBAC)
  • Joint Bookrunner in the SEK 1.11 billion Capital Increase by Oncopeptides
  • Joint Global Coordinator and Joint Bookrunner in the SEK 962 million Capital Increase by BioInvent
  • Co-Manager in the USD 115 million US Public Offering by Y-mAbs Therapeutics
  • Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
  • Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
  • Co-Manager in the USD 190 million Nasdaq Initial Public Offering by Pharvaris
  • Bookrunner in the USD 518 million US Public Offering by CureVac
  • Lead Manager in the USD 120 million US Public Offering by Merus 
  • Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
  • Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
  • Financial Adviser to DCprime in its merger with Immunicum 

Contact

Jan De Kerpel
Thomas ten Hoedt

Transactions